Erdheim-Chester DiseaseSymptoms, Doctors, Treatments, Advances & More
Erdheim-Chester Disease Overview
Learn About Erdheim-Chester Disease
Erdheim-Chester disease is a rare type of slow-growing blood cancer called a histiocytic neoplasm, which results in overproduction of cells called histiocytes. Histiocytes normally function to destroy foreign substances and protect the body from infection. In Erdheim-Chester disease, the excess production of histiocytes (histiocytosis) leads to inflammation that can damage organs and tissues throughout the body, causing them to become thickened, dense, and scarred (fibrotic); this tissue damage may lead to organ failure.
More than half of people with Erdheim-Chester disease have a specific mutation in the BRAF gene. Mutations in other genes are also thought to be involved in this disorder.
Erdheim-Chester disease is a rare disorder; its exact prevalence is unknown. More than 500 affected individuals worldwide have been described in the medical literature. For unknown reasons, men are slightly more likely to develop the disease, accounting for about 60 percent of cases.
This condition is not inherited. It arises from a somatic mutation in histiocytes or their precursor cells during an individual's lifetime.
J Haroche practices practicing medicine in Paris, France. Haroche is rated as an Elite expert by MediFind in the treatment of Erdheim-Chester Disease. They are also highly rated in 19 other conditions, according to our data. Their clinical expertise encompasses Erdheim-Chester Disease, Histiocytosis, Reticulohistiocytoma, Tissue Biopsy, and Splenectomy.
Fleur Aubart-Cohen practices practicing medicine in Paris, France. Ms. Aubart-Cohen is rated as an Elite expert by MediFind in the treatment of Erdheim-Chester Disease. She is also highly rated in 18 other conditions, according to our data. Her clinical expertise encompasses Erdheim-Chester Disease, Non-Langerhans-Cell Histiocytosis, Histiocytosis, Splenectomy, and Heart Transplant.
Zahir Amoura practices practicing medicine in Paris, France. Mr. Amoura is rated as an Elite expert by MediFind in the treatment of Erdheim-Chester Disease. He is also highly rated in 44 other conditions, according to our data. His clinical expertise encompasses Erdheim-Chester Disease, Non-Langerhans-Cell Histiocytosis, Reticulohistiocytoma, Splenectomy, and Kidney Transplant.
Summary: This clinical trial is looking at two drugs called dabrafenib and trametinib. Dabrafenib and trametinib are approved as standard of care treatment for adult patients with melanoma (a type of skin cancer) or lung cancer and in children with glioma (a type of brain tumour). This means they have gone through clinical trials and been approved by the Medicines and Healthcare products Regulatory Agency ...
Summary: This study is being done to answer the following question: What are the supportive care needs of informal caregivers of people with Erdheim-Chester disease and other histiocytic diseases?
Published Date: April 01, 2017
Published By: National Institutes of Health